Monoclonal antibody for the treatment of acute graft versus host disease;Place des anticorps monoclonaux dans le traitement de la maladie aiguë du greffon contre l'hôte en 2006

Bulletin du Cancer

Volumn 94, Issue 1, 2007, Pages 33-41

  Bay, Jacques Olivier ^a   Cabrespine, Aurélie ^a   Peffault De Latour, Régis ^b  

^a CENTRE JEAN PERRIN   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Acute graft versus host disease; Monoclonal antibodies

Indexed keywords

BASILIXIMAB; CD147 ANTIBODY; DACLIZUMAB; ETANERCEPT; INFLIXIMAB; INOLIMOMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; BACTERIAL INFECTION; CELL DAMAGE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG RESISTANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MORBIDITY; MYALGIA; MYCOSIS; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE ACTIVATION; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; ANTIGENS, CD147; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33846902873     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2007.0184     Document Type: Review

References (55)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006 ; 27 : 1813-26.
2. Michallet M, Dhedin N, Michallet AS. [Allogeneic hematopoietic stem-cell transplantation for hematological malignancies]. Bull Cancer 2001 ; 88 : 908-26.
3. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991 ; 324 : 667-74.
4. Tiberghien P, Robinet E, Ferrand C, Saas P, Herve P. [Allorecognition of the recipient after hematopoietic transplantation]. Bull Cancer 2003 ; 90 : 706-10.
5. Couriel D, Caldera H, Champlin R, Komanduri K. Acute graft-versus-host disease : pathophysiology, clinical manifestations, and management. Cancer 2004 ; 101 : 1936-46.
6. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974 ; 18 : 295-304.
7. Ruucu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe : a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997 ; 19 : 759-64.
8. Antin JH, Chen AR, Couriel DR, Ho VT, Nash RA, Weisdorf D. Novel approaches to the therapy of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 2004 ; 10 : 655-68 ; (1990 ; 76 : 1464-72).
9. Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B, et al. Acute upper gastrointestinal graft-versus-host disease : clinical significance and response to immunosuppressive therapy. Blood 1990 ; 76 : 624-9.
10. Basara N, Gunzelmann S, Willenbacher W, Fauser AA, Kiehl MG. New immunosuppressants in BMT/GVHD. Transplant Proc 2001 ; 33 : 2220-2.
11. Storb R, Gluckman E, Thomas ED, Buckner CD, Clift RA, Fefer A, et al. Treatment of established human graft-versus-host disease by antithymocyte globulin. Blood 1974 ; 44 : 56-75.
12. Anasetti C, Martin PJ, Storb R, Appelbaum FR, Beatty PG, Davis J, et al. Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody. Transplantation 1992 ; 54 : 844-51.
13. Khoury H, Kashyap A, Adkins DR, Brown RA, Miller G, Vij R, et al. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant 2001 ; 27 : 1059-64.
14. Remberger M, Aschan J, Barkholt L, Tollemar J, Ringden O. Treatment of severe acute graft-versus-host disease with anti-thymocyce globulin. Clin Transplant 2001 ; 15 : 147-53.
15. Billingham RE. The biology of graft-versus-host reactions. Harvey Lect 1966-1967 ; 62 : 21-78.
16. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006 ; 43 : 3-10.
17. Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002 ; 8 : 575-81.
18. Cooke KR, Hill GR, Crawford JM, Bungard D, Brinson YS, Delmonte-Jr. J, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest 1998 ; 102 : 1882-91.
19. Ferrara JL, Levy R, Chao NJ. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 1999 ; 5 : 347-56.
20. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation : requirement of B7-CD28 signaling through CD40. Science 1996 ; 273 : 1862-4.
21. den Haan JM, Sherman NE, Blokland E, Huczko E, Koning F, Drijfhout JW, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995 ; 268 : 1476-80.
22. Goulmy E, Schipper R, Pool J, Blokland E, Falkenburg JH, Vossen J, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996 ; 334 : 281-5.
23. Koch C, Staffler G, Huttinger R, Hilgett I, Prager E, Cerny J, et al. T cell activation-associated epitopes of CD147 in regulation of the T cell response, and their definition by antibody affinity and antigen density, Int Immunol 1999 ; 11 : 777-86.
24. Jaksch M, Mattsson J. The pathophysiology of acute graft-versus-host , disease. Scand J Immunol 2005 ; 61 : 398-409.
25. New JY, Li B, Koh WP, Ng HK, Tan SY, Yap EH, et al. T cell infiltration and chemokine expression : relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant 2002 ; 29 : 979-86.
26. Graubert TA, DiPersio JF, Russell JH, Ley TJ. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest 1997 ; 100 : 904-11.
27. Hattori K, Hirano T, Miyajima H, Yamakawa N, Tateno M, Oshimi K, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998 ; 91 : 4051-5.
28. van Bekkum DW, Knaan S. Role of bacterial microflora in development of intestinal lesions from graft-versus-host reaction. J Natl Cancer Inst 1977 ; 58 : 787-90.
29. Faucher C. [Mini-allografts of bone marrow (hematology and solid tumors)]. Bull Cancer 2001 ; 88 : 110-3.
30. Murphy WJ, Blazar BR. New strategies for preventing graft-versus-host disease. Curr Opin Immunol 1999 ; 11 : 509-15.
31. Tamada K, Tamura H, Flies D, Fu YX, Celis E, Pease LR, et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002 ; 109 : 549-57.
32. Kobbe G, Schneider P, Rohr U, Fenk R, Neumann F, Aivado M, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody. Bone Marrow Transplant 2001 ; 28 : 47-9.
33. Yamane T, Yamamura R, Aoyama Y, Nakamae H, Hasegawa T, Sakamoto C, et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma 2003 ; 44 : 2095-7.
34. Patriarca F, Sperotto A, Damiani D, Morreale G, Bonifazi F, Olivieri A, et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 2004 ; 89 : 1352-9.
35. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 2004 ; 104 : 649-54.
36. Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients : a cohort study. Blood 2003 ; 102 : 2768-76.
37. Uberti JP, Ayash L, Ratanatharathorn V, Silver S, Reynolds C, Becker M, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005 ; 11 : 680-7.
38. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007 ; 82 : 45-52.
39. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 1995 ; 345 : 1144-6.
40. Anasetti C, Martin PJ, Storb R, Appelbaum FR, Beatty PG, Calori E, et al. Prophylaxis of graft-versus-host disease by administration of the murine anti-IL-2 receptor antibody 2A3. Bone Marrow Transplant 1991 ; 7 : 375-81.
41. Herve P, Bordigoni P, Cahn JY, Flesch M, Tiberghien P, Racadot E, et al. Use of monoclonal antibodies in vivo as a therapeutic strategy for acute GvHD in matched and mismatched bone marrow transplantation. Transplant Proc 1991 ; 23 : 1692-4.
42. Cuthbert RJ, Phillips GL, Barnett MJ, Nantel SH, Reece DE, Shepherd JD, et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplant 1992 ; 10 : 451-5.
43. Herbelin C, Stephan JL, Donadieu J, Le Deist F, Racadot E, Wijdenes J, et al. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants. Bone Marrow Transplant 1994 ; 13 : 563-9.
44. Bay JO, Dhedin N, Goerner M, Vannier JP, Marie-Gardine A, Stamatoullas A, et al. Inolimomab in steroid-refractory acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation : retrospective analysis and comparison with other interleukin-2 receptor antibodies. Transplantation 2005 ; 80 : 782-8.
45. Cahn JY, Bordigoni P, Tiberghien P, Milpied N, Brion A, Widjenes J, et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 1995 ; 60 : 939-42.
46. Anasecti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac : an antibody that binds to the interleukin-2 receptor. Blood 1994 ; 84 : 1320-7.
47. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000 ; 95 : 83-9.
48. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy Jr. PL, et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease : results of a randomized trial. Blood 2004 ; 104 : 1559-64.
49. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplant 2002 ; 30 : 899-903.
50. Schmidt-Hieber M, Fietz T, Knauf W, Uharek L, Hopfenmuller W, Thiel E, et al. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease. Br J Haematol 2005 ; 130 : 568-74.
51. Funke VA, de Medeiros CR, Setubal DC, Ruiz J, Bitencourt MA, Bonfim CM, et al. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. Bone Marrow Transplant 2006 ; 37 : 961-5.
52. Deeg HJ, Blazar BR, Bolwell BJ, Long GD, Schuening F, Cunningham J, et al. Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL. Blood 2001 ; 98 : 2052-8.
53. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, et al. A phase II/III multi-center randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood 2006 : 16 ; (Epub ahead of print).
54. Wolff TD, Roessler V, Steiner B, Wilhelm S, Weirich V, Brenmoehl J, et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005 ; 35 : 1003-10.
55. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer 2005 : 31.